Bull Risk Reversal in Allakos (ALLK) Targets Q4 Data
Allakos (ALLK) on an impressive three week rally and today seeing the December $125 calls bought 600X for $19.40 while the $85 puts are sold to open 600X for $15.60, bull risk reversals. ALLK has 1500 January $130 calls in OI from buyers. The $5.3B Biotech will report lirentelimab data in eosinophilic gastrointestinal disease in Q4. HCW started shares Buy in May with a $230 target noting that lirentelimab could over the long-term become one of the largest drugs ever based on peak annual revenues.